Aducanumab: evidence from clinical trial data and controversies
Alzheimer’s disease (AD) is the most common cause for dementia worldwide. Until recently, all approved treatments for AD were symptomatic and not disease modifying. On 7 June 2021, the US FDA approved aducanumab, a human IgG1 anti-Aβ monoclonal antibody selective for Aβ aggregates, as the first dise...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2021-10-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/aducanumab-evidence-from-clinical-trial-data-and-controversies |
| _version_ | 1818887574407610368 |
|---|---|
| author | Rajesh R Tampi Brent P Forester Marc Agronin |
| author_facet | Rajesh R Tampi Brent P Forester Marc Agronin |
| author_sort | Rajesh R Tampi |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is the most common cause for dementia worldwide. Until recently, all approved treatments for AD were symptomatic and not disease modifying. On 7 June 2021, the US FDA approved aducanumab, a human IgG1 anti-Aβ monoclonal antibody selective for Aβ aggregates, as the first disease-modifying treatment for AD. Aducanumab is approved in the United States for the treatment of mild cognitive impairment or mild-dementia stage of AD. In this Editorial, we review the trial data for aducanumab in the treatment of AD and the controversies that its approval has generated. |
| first_indexed | 2024-12-19T16:39:24Z |
| format | Article |
| id | doaj.art-74d741d2fa144a82aa5f8127c0ad48ca |
| institution | Directory Open Access Journal |
| issn | 1740-4398 |
| language | English |
| last_indexed | 2024-12-19T16:39:24Z |
| publishDate | 2021-10-01 |
| publisher | BioExcel Publishing Ltd |
| record_format | Article |
| series | Drugs in Context |
| spelling | doaj.art-74d741d2fa144a82aa5f8127c0ad48ca2022-12-21T20:13:51ZengBioExcel Publishing LtdDrugs in Context1740-43982021-10-01101910.7573/dic.2021-7-3Aducanumab: evidence from clinical trial data and controversiesRajesh R TampiBrent P ForesterMarc AgroninAlzheimer’s disease (AD) is the most common cause for dementia worldwide. Until recently, all approved treatments for AD were symptomatic and not disease modifying. On 7 June 2021, the US FDA approved aducanumab, a human IgG1 anti-Aβ monoclonal antibody selective for Aβ aggregates, as the first disease-modifying treatment for AD. Aducanumab is approved in the United States for the treatment of mild cognitive impairment or mild-dementia stage of AD. In this Editorial, we review the trial data for aducanumab in the treatment of AD and the controversies that its approval has generated.https://www.drugsincontext.com/aducanumab-evidence-from-clinical-trial-data-and-controversiesβ-amyloidaducanumabalzheimer’s diseaseamyloid-related imaging abnormalitiesanti-aβ monoclonal antibodydementianeurofibrillary tanglestau proteins |
| spellingShingle | Rajesh R Tampi Brent P Forester Marc Agronin Aducanumab: evidence from clinical trial data and controversies Drugs in Context β-amyloid aducanumab alzheimer’s disease amyloid-related imaging abnormalities anti-aβ monoclonal antibody dementia neurofibrillary tangles tau proteins |
| title | Aducanumab: evidence from clinical trial data and controversies |
| title_full | Aducanumab: evidence from clinical trial data and controversies |
| title_fullStr | Aducanumab: evidence from clinical trial data and controversies |
| title_full_unstemmed | Aducanumab: evidence from clinical trial data and controversies |
| title_short | Aducanumab: evidence from clinical trial data and controversies |
| title_sort | aducanumab evidence from clinical trial data and controversies |
| topic | β-amyloid aducanumab alzheimer’s disease amyloid-related imaging abnormalities anti-aβ monoclonal antibody dementia neurofibrillary tangles tau proteins |
| url | https://www.drugsincontext.com/aducanumab-evidence-from-clinical-trial-data-and-controversies |
| work_keys_str_mv | AT rajeshrtampi aducanumabevidencefromclinicaltrialdataandcontroversies AT brentpforester aducanumabevidencefromclinicaltrialdataandcontroversies AT marcagronin aducanumabevidencefromclinicaltrialdataandcontroversies |